+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
R

Actively Recruiting

Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.

Age: 18Years +All GendersPhase 3
39 locations
E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma who have received multiple prior treatments. This Phase 2 study focuses on determining the recommended doses and assessing the treatment in different participant groups based on previous therapies received. The study is sponsored by Janssen Research & Development, LLC and aims to provide new treatment options for this condition. Participants are divided into five cohorts based on their treatment history, including exposure to T cell redirection therapies and prior medications. Talquetamab is administered subcutaneously at recommended Phase 2 doses, with dosing schedules including biweekly administration in some cohorts. All participants will transition to an open-label extension phase to continue receiving the study treatment, followed by a long-term extension phase upon sponsor approval. Throughout the study, participants will undergo regular assessments to measure treatment response, safety, and tolerability. These include evaluations of overall response rate, duration of response, progression-free survival, quality of life questionnaires, laboratory tests, and monitoring for adverse events. The study duration includes follow-up to approximately 2 years and 10 months. Talquetamab concentrations and antibody presence will also be monitored to understand treatment effects and immune response.

Age: 18Years +All GendersPhase 2
78 locations
E

Actively Recruiting

Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.

Age: 12Years - 17YearsAll GendersPhase 3
30 locations
P

Actively Recruiting

This research aims to compare overall survival in men with chemotherapy-naefve metastatic castration-resistant prostate cancer. The study evaluates the combination of xaluritamig and abiraterone against the investigators choice of treatments, which include abiraterone, docetaxel, or cabazitaxel. The trial is a phase 3, open-label, randomized study sponsored by Amgen. Participants will be randomly assigned to receive either xaluritamig administered intravenously combined with oral abiraterone acetate, or the investigators choice of one of the following treatments daily oral abiraterone acetate, or intravenous docetaxel or cabazitaxel given every three weeks. Treatments continue with regular monitoring throughout the study period, which lasts up to approximately 51 months for outcome assessments. Participants will undergo various assessments including imaging scans such as CT, MRI, or bone scans to confirm metastatic disease and monitor progression. Researchers will also evaluate pain levels, quality of life, prostate-specific antigen PSA responses, and adverse events throughout the study. Follow-up evaluations will continue for up to 51 months to measure survival and other health outcomes, with safety monitoring conducted throughout the participation period.

Age: 18Years +MALEPhase 3
159 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.

Age: 18Years +All GendersPhase 3
165 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.

Age: 18Years +All GendersPhase 3
266 locations

1-10 of 25

1